Cargando…
Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815750/ https://www.ncbi.nlm.nih.gov/pubmed/31695543 http://dx.doi.org/10.2147/JBM.S183857 |
_version_ | 1783463240272969728 |
---|---|
author | Sarosiek, Shayna Sanchorawala, Vaishali |
author_facet | Sarosiek, Shayna Sanchorawala, Vaishali |
author_sort | Sarosiek, Shayna |
collection | PubMed |
description | Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the source of the amyloidogenic light chain. First-line therapies in this disease are well established, but in the relapsed or refractory setting, there are many treatment options, including immunomodulatory agents, proteasome inhibitors, alkylating agents, and monoclonal antibodies. Decisions regarding treatment choice should be made by a multidisciplinary team with consideration of the patient’s functional status, disease stage, degree of organ dysfunction, and potential treatment toxicities. Herein we review the current treatment options available for patients with relapsed or refractory AL amyloidosis. |
format | Online Article Text |
id | pubmed-6815750 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-68157502019-11-06 Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives Sarosiek, Shayna Sanchorawala, Vaishali J Blood Med Review Systemic immunoglobulin light chain (AL) amyloidosis is a disorder characterized by the production of clonal serum free light chains that misfold, aggregate, and deposit in vital organs. Treatment of this disease is typically targeted at the abnormal plasma cell clone in the bone marrow which is the source of the amyloidogenic light chain. First-line therapies in this disease are well established, but in the relapsed or refractory setting, there are many treatment options, including immunomodulatory agents, proteasome inhibitors, alkylating agents, and monoclonal antibodies. Decisions regarding treatment choice should be made by a multidisciplinary team with consideration of the patient’s functional status, disease stage, degree of organ dysfunction, and potential treatment toxicities. Herein we review the current treatment options available for patients with relapsed or refractory AL amyloidosis. Dove 2019-10-23 /pmc/articles/PMC6815750/ /pubmed/31695543 http://dx.doi.org/10.2147/JBM.S183857 Text en © 2019 Sarosiek and Sanchorawala. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Sarosiek, Shayna Sanchorawala, Vaishali Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives |
title | Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives |
title_full | Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives |
title_fullStr | Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives |
title_full_unstemmed | Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives |
title_short | Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives |
title_sort | treatment options for relapsed/refractory systemic light-chain (al) amyloidosis: current perspectives |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815750/ https://www.ncbi.nlm.nih.gov/pubmed/31695543 http://dx.doi.org/10.2147/JBM.S183857 |
work_keys_str_mv | AT sarosiekshayna treatmentoptionsforrelapsedrefractorysystemiclightchainalamyloidosiscurrentperspectives AT sanchorawalavaishali treatmentoptionsforrelapsedrefractorysystemiclightchainalamyloidosiscurrentperspectives |